NCT01769898View on ClinicalTrials.gov

The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

November 30, 2014

Conditions
Bronchiectasis
Interventions
DRUG

Formoterol-budesonide

Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)

DRUG

Theophylline

Theophylline 0.1 Q12H

DRUG

Placebo

Placebo for theophylline 0.1 Q12H

Trial Locations (2)

510000

State Key Laboratory of Respiratory Research Institute., Guangzhou

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER

NCT01769898 - The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis | Biotech Hunter | Biotech Hunter